Overview

A Multicenter, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Once Daily Mirvaso® Gel in Patients With Chronic Persistent Vascular Facial Erythema.

Status:
Completed

Trial end date:
2017-02-08

Target enrollment:

Participant gender:

Summary

This study evaluates the efficacy of Mirvaso® in the treatment of chronic persistent vascular facial erythema, after 4 weeks of treatment, by the Clinician erythema assessment.

Phase:

Phase 4

Details

Lead Sponsor:

Galderma Brasil Ltda.

Collaborator:

Eurotrials Brasil Consultores Cientificos Ltda

Treatments:

Brimonidine Tartrate